Geron (GERN) Assets Average (2011 - 2026)
Geron (GERN) posted Assets Average of $552.3 million for Q1 2026, down 2.92% sequentially from $569.0 million in Q4 2025, and down 4.46% YoY from $578.1 million in Q1 2025.
Geron (GERN) Assets Average (2011 - 2026) Analysis & Trends
Geron has reported Assets Average for 16 years, with the latest figure at $552.3 million in Q1 2026.
- Quarterly Assets Average fell 4.46% year-over-year to $552.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $552.3 million (down 4.46% YoY) and the FY2025 annual result came in at $582.2 million, up 17.86% from the prior year.
- Assets Average slipped to $552.3 million in Q1 2026 per GERN's latest filing, from $569.0 million in the prior quarter.
- Over five years, Assets Average peaked at $578.1 million in Q1 2025 and troughed at $211.6 million in Q4 2022.
- A 5-year average of $418.4 million and a median of $438.1 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average declined 19.81% in 2022, then soared 92.44% in 2023.
- Over 5 years, Assets Average stood at $211.6 million in 2022, then soared by 90.72% to $403.5 million in 2023, then grew by 28.7% to $519.4 million in 2024, then gained by 9.55% to $569.0 million in 2025, then decreased by 2.92% to $552.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $552.3 million, $569.0 million, and $561.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 19.82 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 526.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 526.56 Mn |
| Mar 31, 2026 | 552.33 Mn |
| Dec 31, 2025 | 568.96 Mn |
| Sep 30, 2025 | 561.29 Mn |
| Jun 30, 2025 | 558.82 Mn |
| Mar 31, 2025 | 578.12 Mn |
| Dec 31, 2024 | 519.37 Mn |
| Sep 30, 2024 | 447.17 Mn |
| Jun 30, 2024 | 465.74 Mn |
| Mar 31, 2024 | 438.08 Mn |
| Dec 31, 2023 | 403.55 Mn |
| Sep 30, 2023 | 414.16 Mn |
| Jun 30, 2023 | 420.09 Mn |
| Mar 31, 2023 | 307.73 Mn |
| Dec 31, 2022 | 211.59 Mn |
| Sep 30, 2022 | 235.38 Mn |
| Jun 30, 2022 | 218.29 Mn |
| Mar 31, 2022 | 212.23 Mn |
| Dec 31, 2021 | 227.57 Mn |
| Sep 30, 2021 | 240.64 Mn |